Media Center

In the media

A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer

RAC1

06/06/2019

Nine Catalan biotechs among the most promising in Europe

La Vanguardia

28/05/2019

AbilityPharma will start research for cancer in China

El Punt Avui

05/02/2019

The partner of AbilityPharma in China starts clinical trials with the licensed drug

Expansión

04/02/2019

AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell

Ara

10/12/2018

AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA

Expansión

08/11/2018

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

The FDA approves a clinical trial of AbilityPharma

Expansión

20/02/2018

Ability Pharma gets FDA nod for a new clinical trials

Diari de Sabadell

20/02/2018

Ability receives FDA authorization to start clinical trials

Expansión

14/12/2017

Ability Pharma seeks 2.5 million to expand clinical trials

Expansión

09/10/2017

Ability Pharma receives the OK from France for testing a new drug

Diari Sabadell

09/10/2017

ABILITY PHARMA ACHIEVES THE DISTINCTION OF ORPHAN DRUG IN THE EU

Expansión

19/09/2017

REWARD TO MINORYX AND ABILITY AUDACITY

Expansión

15/12/2016

Ability Pharma strengthens in the US

El Periódico

14/12/2016

AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812

Diari de Sabadell

06/12/2016

The phase 2 of the antitumoral drug starts

La Vanguardia

23/11/2016

LATEST NEWS

31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG